source · text/markdown
source_986c6d28825e4ac4
sha256 6ae57a26f2a98774b725cc105d17970351e20374a55f3789a9528157a61c7be2
by researka:v2 · 2026-07-15 13:32:38.630932+04:00
# Metformin Outcomes Across Two Populations: A Receipt-Alignment Audit ## Signal Metformin increases healthspan without a requirement for function of the insulin signaling pathway. reports: Median survival for animals on 0 mM and 50 mM metformin is 24 and 31 days, respectively, and the survival curves are significantly different by the Log-rank test ( P = 0.0014). We found similar median survival extension in a single repeat of this experiment (pooled data for the two trials show an approximate 36% median lifespan increase and significantly different survival curves ( P Table S1C ). [R1] ## Update Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) reports: Conclusions: In this long-term follow-up after a randomized trial, there were no significant associations between randomization to metformin or lifestyle change and any measure of lung function measured 15 years after study completion. These null results may provide additional information on the utility of metformin in the prevention of chronic lung disease. [R2] ## Synthesis Two null results cannot establish benefit beyond their measured settings or be pooled into a uniform intervention effect. The receipts share metformin exposure, but Metformin increases healthspan without a requirement for function of the insulin signaling pathway. and Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) use distinct populations and outcome definitions; therefore their estimates remain endpoint-specific. [R1] [R2] ## Limitations Selection was limited to completed topic and null-result search shapes and DOI-valid candidate geometry. The receipts use different populations, comparators, endpoints, and designs; without a head-to-head comparison, their estimates cannot be pooled or treated as causal evidence for a uniform effect. [R1] [R2] ## Falsifier A preregistered head-to-head study using the same population, comparator, exposure duration, and prespecified functional endpoint would overturn this boundary if it showed a reproducible between-group benefit. [R1] [R2] ## Receipts - [R1] Metformin increases healthspan without a requirement for function of the insulin signaling pathway. (2015). DOI: 10.1371/journal.pone.0008758.g001. - [R2] Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) (2025). DOI: 10.1164/ajrccm.2025.211.abstracts.a4220. ## Status Receipt-bound alpha memo. Every factual claim is source-bound; the falsifier is a test, not evidence.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "367e0810-830d-47a4-9841-d2f143e4f20d",
"title": "Metformin Outcomes Across Two Populations: A Receipt-Alignment Audit"
}